SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the ...

THOUSAND OAKS, Calif., November 12, 2006 -- Amgen (NASDAQ: AMGN) today announced that Enbrel? (etanercept) is the first biologic with published data to show improvements in multiple measures of ...

LONDON – A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the ...

LONDON (Reuters) - A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light ...

The psoriasis-easing effect of Enbrel, a drug that dampens inflammatory immune responses, lasts for at least two years, a large-scale clinical trial shows. Enbrel acts like a very specific sponge that ...

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...

WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...

In Amgen’s latest campaign for Enbrel, kids are speaking up. Two new TV commercials feature children talking about their parents’ painful arthritis and their worries about it. The “Being There” ...

ONYX-015 is a chimeric human group C adenovirus (Ad2 and Ad5) that does not express the 55 kDa product of the E1B gene. The virus contains a deletion between nucleotides 1496 and 3323 in the E1B ...

A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents. In a 2-1 decision, the ...